Cargando…
Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report
INTRODUCTION: Chimeric antigen receptor T cells (CAR-T) targeting CD19 have shown great potential for treatment of B-cell malignancies. For those patients who can not achieve complete remission (CR) or suffer from relapse after CAR-T therapy, further therapeutic strategies still remain elusive. Whet...
Autores principales: | Liang, Zuyu, Zhang, Hao, Shao, Mi, Cui, Qu, Wu, Zhao, Xiao, Lei, Huang, He, Hu, Yongxian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7581168/ https://www.ncbi.nlm.nih.gov/pubmed/33120740 http://dx.doi.org/10.1097/MD.0000000000022510 |
Ejemplares similares
-
Chylothorax after chimeric antigen receptor T cell therapy for relapsed and refractory diffuse large B-cell lymphoma: A case report
por: Chen, Hsin-Hui, et al.
Publicado: (2023) -
Pleural cavity cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy: A case report
por: Ding, Lijuan, et al.
Publicado: (2018) -
Chimeric antigen receptor-modified T-cell therapy for bone marrow and skin relapse Philadelphia chromosome-like acute lymphoblastic leukemia: A case report
por: Yang, Mianzeng, et al.
Publicado: (2020) -
Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma: A systematic review and meta-analysis
por: Cao, Genmao, et al.
Publicado: (2019) -
Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report
por: Yagi, Yu, et al.
Publicado: (2021)